Alight Launches GLP-1 Reimbursement Account to Help Employers Control Drug Costs

Benefits administration provider Alight, Inc. (NYSE:ALIT) introduced a specialized health reimbursement account designed to help employers finance and manage employee access to GLP-1 medications. The new product enables companies to set reimbursement caps, choose custom funding structures, and provide employees with a digital portal to submit eligible medication costs while remaining compliant with tax rules for high-deductible health plans.

The launch comes as surging demand for GLP-1 treatments creates significant cost pressure on corporate health benefit budgets. Internal data from the company shows that GLP-1 drugs represented 42% of prescription reviews across its navigation business, rising from 32% in 2024. Furthermore, lower-cost alternatives were identified in 16% of those reviews, offering average annual savings of $2,790 per prescription.

Investors and healthcare analysts will watch how quickly corporate clients adopt the new reimbursement framework and whether it helps stem rising benefit spending. Market participants will also monitor whether the tool boosts client retention and drives revenue growth for the firm amid broader shifts in weight-loss drug coverage.